Neuralink announced on Tuesday that it has performed the first implantation of its electrode threads directly through the brain’s protective dura membrane in a human clinical trial participant, leaving the dura intact.
The procedure took place at University Health Network’s Toronto Western Hospital in Canada. The participant began controlling a computer cursor with their thoughts within an hour of surgery, with recovery progressing as expected.
Background and Surgical Challenge
The dura mater is a tough, leathery membrane that acts as the brain’s primary protective layer, often described as its “armor.”
In traditional neurosurgery and prior Neuralink procedures, surgeons performed a durectomy—cutting or removing part of this membrane—to access the cortex below. This step is delicate because the dura can be over 10 times thicker than Neuralink’s electrode threads, which are thinner than a human hair. The brain moves constantly beneath it, and the membrane obscures blood vessels that must be avoided.
Neuralink’s earlier implants required this incision, adding a manual, high-precision step to the surgery. The company has long aimed to simplify the process for safety and scalability. As early as January 2026, Neuralink outlined plans to explore transdural insertions to reduce invasiveness.
The Breakthrough Procedure
In this first-of-its-kind clinical trial procedure, performed in May 2026 alongside neurosurgeon Dr. Andres Lozano at Toronto Western Hospital, surgeons inserted the ultra-thin electrode threads straight through the intact dura and into the cortex.
This first-of-its-kind procedure was performed at @UHN Toronto Western Hospital as part of our clinical trials. The participant was controlling a cursor with their thoughts within an hour of surgery, and recovery is progressing as expected.
Neuralink devices are investigational…
— Neuralink (@neuralink) June 30, 2026
This required advanced transdural imaging to visualize vessels through the opaque tissue and precision-engineered needles capable of piercing the tough membrane reliably. Extensive preclinical testing validated the approach before human use.
“We like to say ‘the best step is no step’ and deleting the durectomy takes one of the most delicate manual steps out of the procedure. This potentially means a safer, more repeatable surgery, and a real path to scaling Neuralink to the many people who could benefit,” stated Neuralink.
Elon Musk, Neuralink co-founder, commented that “Neuralink has solved through-dura electrode implantation! This is a very big deal, as it greatly improves the safety and ease of interfacing with the brain.”
Neuralink has solved through-dura electrode implantation!
This is a very big deal, as it greatly improves the safety and ease of interfacing with the brain. https://t.co/NV59xKAE22
— Elon Musk (@elonmusk) June 30, 2026
Current Status of Neuralink Trials
As of January 2026, Neuralink reported 21 participants enrolled in its trials worldwide.
The company is focused on helping people with quadriplegia from spinal cord injury or amyotrophic lateral sclerosis (ALS) control computers, robotic arms, and other devices through thought.
Patients in the PRIME and CAN-PRIME studies have demonstrated control of cursors, gaming, and other digital interfaces. The Toronto Western Hospital serves as the exclusive Canadian site for the CAN-PRIME study.
Neuralink devices remain investigational and have not received full approval from the FDA or other regulatory authorities.
Path Forward and Potential Outcomes
Future iterations may include increased electrode counts for higher-resolution signals and improved thread retention for long-term stability. Applications under exploration include restoring vision (Blindsight), speech, and motor function.
Success in scaling could expand access for patients with paralysis or neurological conditions. Long-term outcomes will depend on ongoing trial data, regulatory review, and further engineering refinements. Neuralink continues to iterate on both hardware and procedures while maintaining a record of zero serious device-related adverse events in its reported clinical experience.
The company has published a detailed video thread explaining the technique and its implications.
